Bloch Stephen M sold $7.6M of LQDA (indirect holdings)

Bloch Stephen M sold 100,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $75.74 ($75.54–$76.18, $7.57M total) across 2 trades on 2026-06-22.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed open-market sale provides a fresh, filing-based datapoint on insider behavior, but it does not include new guidance, trial results, or regulatory outcomes.

02

Market read

Traders may briefly reassess sentiment around LQDA based on the size of the director sale, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamentals.

03

What to watch

The transaction is described as indirect holdings and does not clarify tax/estate mechanics; traders should watch for subsequent filings (additional sales/buys) and any concurrent company news.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA) by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 100,000 shares in open-market transactions on 2026-06-22 for about $7.57M total value.

Expected impact

Likely limited, short-lived impact unless follow-on selling or new company fundamentals emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with disclosed sale size and price range, but it provides no new operational/financial information; also notes no 10b5-1 plan.

Market effects

Minimal; this is company-specific insider selling with no sector-wide regulatory/earnings signal.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events; without a 10b5-1 plan, the sale still may reflect pre-existing personal needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure (LQDA).

  • Stephen M. Bloch

    Director who sold 100,000 shares in open-market transactions on 2026-06-22; indirect holdings; no 10b5-1 plan stated.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.